Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Sophiris Bio, Inc. SPHS OTC

Other OTC • Healthcare • Biotechnology • US • USD

SharesGrow Score
52/100
2/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Sophiris Bio, Inc. (SPHS) is a Biotechnology company in the Healthcare sector, currently trading at $0.00. It has a SharesGrow Score of 49/100, indicating a mixed investment profile with 2 out of 7 criteria passed.

Net income is $7M (loss), growing at +20.5%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $7M against $2M equity (Debt-to-Equity (D/E) ratio 4.04, leveraged). Current ratio is 2.65 (strong liquidity). Debt-to-assets is 53.1%. Total assets: $13M.

Analyst outlook: 3 / 3 analysts rate SPHS as buy (100%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 100/100 (Pass), Past 0/100 (Fail), Health 33/100 (Fail), Moat 28/100 (Fail), Future 100/100 (Pass), Income ?/100 (Fail).

SPHS SharesGrow Score Overview

65/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 100/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 33/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 28/100
Gross margin is + market cap
FUTURE 100/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — SPHS

—
VALUE N/A
N/A
No analyst coverage available for this stock.
✓
GROWTH Pass
100/100
SPHS: +0%/yr revenue is, +20.5%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✗
HEALTH Fail
33/100
Balance sheet SPHS: Debt-to-Equity (D/E) ratio 4.04 (leveraged), Current ratio is 2.65 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
28/100
SPHS: Gross margin is 0% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 28/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
100/100
Analyst outlook: 3 / 3 analysts rate SPHS as buy (100%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range0.000001-0.000001
Volume1K
Avg Volume (30D)16
Beta (1Y)-33.39
Share Statistics
EPS (TTM)-0.25
Shares Outstanding$30.12M
IPO Date2008-11-18
Employees6
Financial Highlights & Ratios
EBITDA$-6.09M
Net Income$-7.46M
Operating Income$-6.09M
Total Cash$12.54M
Total Debt$7.01M
Net Debt$-3.99M
Total Assets$13.2M
Price / Earnings (P/E)-0
Analyst Forecast
Rating ConsensusBuy
Analysts Covering3
Buy 100% Hold 0% Sell 0%
Company Info
CountryUS
ExchangeOther OTC
CurrencyUSD
ISINCA83578Q2099

Price Chart

Track all markets on TradingView
SPHS
Sophiris Bio, Inc. ↗  ·  Other OTC
Healthcare • Biotechnology

People Also View

LLY
LLY
Eli Lilly and Company
$922.50
-0.76%
 JNJ
JNJ
Johnson & Johnson
$240.10
+0.90%
 ABBV
ABBV
AbbVie Inc.
$210.32
+1.86%
 RHHBF
RHHBF
Roche Holding AG
$418.50
+1.82%
 RHHBY
RHHBY
Roche Holding AG
$51.02
+0.65%
 AZN
AZN
AstraZeneca PLC
$204.38
+1.06%
 NVSEF
NVSEF
Novartis AG
$156.48
+0.00%
 MRK
MRK
Merck & Co., Inc.
$119.96
-0.16%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message